Optimization of the Duration of the Administration of Mesenchymal Stem Cells Wharton’s Jelly to the Level of Matrix Metalloproteinase-1 and Transforming Growth Factor-β in Osteoarthritis Rat Model

Endrinaldi, Endrinaldi; Ali, Hirowati; Tofrizal, Tofrizal; Asterina, Asterina; Elmatris, Elmatris; Yarni, Sisca Dwi

doi:10.3889/oamjms.2022.8838

Cited by 1 publication

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 30 Another trial showed that WJ-MSCs had a net positive effect on MMP-1 and TGF-beta levels. 38 A further investigation by the same group confirmed that the MMP-1 and IL4 markers were elevated after the introduction of WJ-MSCs compared to the control group. 39 The conflicting outcomes may result from a need for standardized testing methods, indicating a need for additional meticulously designed studies to definitively establish the suitability of WJ-MSCs as a viable biologic for the management of knee OA.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Wharton’s jelly and osteoarthritis of the knee

Aratikatla,

Maffulli,

Gupta

et al. 2023

British Medical Bulletin

View full text Add to dashboard Cite

Introduction The existing treatment modalities for knee osteoarthritis (OA) do not actually address the pathology. Biological therapies, including those using material derived from perinatal tissues, represent a ground-breaking approach to alleviating the symptoms of OA of the knee. Source of data Current scientific literature published in PubMed (MEDLINE), Embase and Scopus databases. Trials registered in various clinical trial databases. Areas of agreement Perinatal tissues including Wharton’s jelly (WJ) and associated mesenchymal stem cells (MSCs) can be used for the management of knee OA. Areas of controversy The efficacy of WJ and associated MSCs in the management of knee OA is still controversial. Growing points The use of WJ and associated MSCs in the management of knee OA is safe and appears to be effective. Areas timely for developing research The present published evidence suggests that WJ tissue and associated MSCs offer an encouraging alternative for the management of knee OA. The published in vitro, preclinical and clinical investigations demonstrate the therapeutic potential of WJ and promote further research in this field to provide symptomatic relief to patients suffering from OA, aiming also to regenerate the osteoarthritic hyaline cartilage, with disease-modifying effects. Future adequately powered randomized controlled trials should be undertaken to establish whether WJ is helpful in the management of OA of the knee.

show abstract

Section: Discussionmentioning

confidence: 85%

“…Further preclinical and clinical studies should determine whether this is an effective biologic treatment to aid the progression of knee OA. 38 …”

Section: Resultsmentioning

confidence: 99%